Get 40% Off
💰 Ray Dalio just increased his holdings in Google by 162.61% - See the full portfolio with InvestingPro’s free Stock Ideas toolCopy Portfolios

U.S. seeks more than eight years prison for SAC's Martoma

Published 28/06/2014, 00:59
U.S. seeks more than eight years prison for SAC's Martoma
PFE
-
PRGO
-

By Nate Raymond

NEW YORK (Reuters) - Mathew Martoma, a former SAC Capital Advisors portfolio manager convicted of insider trading, should be sentenced to a "substantial" term of prison beyond the eight years recommended by probation officers, U.S. prosecutors argued Friday.

In court papers filed in New York federal court, prosecutors urged U.S. District Judge Paul Gardephe to impose a prison term for Martoma "toward the high end" of sentences imposed in insider trading cases.

"If the crime of insider trading is a serious one, Martoma stands before the court as one of the very worst offenders," prosecutors wrote.

The court's probation department has recommended Martoma be sentenced to eight years in prison. It had calculated that under the federal sentencing guidelines, Martoma would face between 15 years, 8 months and 19 years, 7 months in prison.

Martoma's lawyers had called those lengths of time "outrageous" and "irrational." Prosecutors on Friday said they also did not oppose a sentence below that range.

But prosecutors under Manhattan U.S. Attorney Preet Bharara told Gardephe he should impose a "substantial" sentence in light of the seriousness of the conduct and the "unprecedented" ill-gotten gains.

Richard Strassberg, a lawyer for Martoma, declined comment.

Martoma, 40, faces sentencing on July 28 after a jury found him guilty in February on conspiracy and securities fraud charges for trading on confidential tips about a clinical trial for an Alzheimer's drug.

Prosecutors said the scheme enabled SAC to make $275 million (161.44 million pounds) in July 2008 from trades in Elan Corp and Wyeth, a record amount in U.S. insider trading cases.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Elan was acquired last year by Perrigo Company Plc (N:PRGO), while Wyeth is now owned by Pfizer Inc (N:PFE).

Martoma is one of eight SAC employees to have been convicted on insider trading charges. SAC, founded by billionaire Steven A. Cohen, pleaded guilty to fraud and agreed to pay $1.8 billion in criminal and civil settlements.

Cohen, 58, has not been criminally charged. He has renamed his Stamford, Connecticut-based firm Point72 Asset Management, and shifted its focus to managing his fortune.

On Friday, SAC Capital reached an agreement with the U.S. Securities and Exchange Commission to no longer be an investment adviser, following the firm's guilty plea.

Cohen continues to face a SEC administrative action for failing to supervise SAC employees who engaged in insider trading, including Martoma. He denies wrongdoing.

The longest U.S. insider trading sentence is a 12-year term given to lawyer Matthew Kluger for a $37 million scheme for which he pleaded guilty in 2011.

The case is U.S. v. Martoma, U.S. District Court for the Southern District of New York, 12-cr-00973.

(Reporting by Nate Raymond in New York; Editing by Bernard Orr)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.